Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Akt and mTOR Pathways Differentially Regulate the Development of Natural and Inducible IL-17-Producing CD4+ T Cells

Jiyeon S Kim, MS, Tammarah Sklarz, Adam Waickman, Ming O Li, PhD, Jeffrey Rathmell, PhD, Morris Birnbaum, MD, PhD, Jonathan Powell, MD, PhD, Martha S Jordan, PhD, Gary A Koretzky, MD, PhD

Blood (2012) 120 (21): 838.

https://doi.org/10.1182/blood.V120.21.838.838

Published: 2012

Journal Articles

Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting

Kimberly Noonan, MPH, Carol A. Huff, MD, Janice M Davis Sproul, MAS, MT(ASCP), SBB, Mario Victor M Lemas, PhD, Lakshmi Rudraraju, MS, Leo Luznik, Jonathan Powell, MD, PhD, Javier Bolaños-Meade, Jeffrey Bitzan, MT, Susan Fiorino, MT(ASCP), William Matsui, MD, Richard J. Jones, MD, Ivan M. Borrello, MD

Blood (2011) 118 (21): 997.

https://doi.org/10.1182/blood.V118.21.997.997

Published: 2011

Journal Articles

Post-Transplant Cyclophosphamide and Sirolimus Are Synergistic in Preventing Rejection and Inducing Stable Mixed Chimerism Independently of Regulatory T Cells.

Courtney Fitzhugh, MD, Matthew M. Hsieh, MD, Oswald Phang, Camille Madison, Leo Luznik, MD, Jonathan Powell, MD, PhD, John F. Tisdale, MD

Blood (2009) 114 (22): 3540.

https://doi.org/10.1182/blood.V114.22.3540.3540

Published: 2009

Journal Articles

Enhanced Interaction Between Hsp90 and Raptor Regulates mTOR Signaling upon T Cell Activation

Greg M Delgoffe, Thomas P. Kole, PhD, Robert J Cotter, PhD, Jonathan Powell, MD, PhD

Blood (2008) 112 (11): 674.

https://doi.org/10.1182/blood.V112.11.674.674

Published: 2008

Journal Articles

TOR Complex 1 and TOR Complex 2 Differentially Regulate Effector and Regulatory T Cell Differentiation

Greg M Delgoffe, Thomas P. Kole, PhD, Yan Zheng, PhD, Bo Xiao, MD, PhD, Paul F. Worley, MD, Sara C Kozma, PhD, Jonathan Powell, MD, PhD

Blood (2008) 112 (11): 675.

https://doi.org/10.1182/blood.V112.11.675.675

Published: 2008

Journal Articles

A Novel Allogeneic Transplant Conditioning Regimen Designed for Tolerance Induction in Patients with Severe Sickle Cell Disease.

Matthew M. Hsieh, MD, Elizabeth M. Kang, MD, Beth Link, Maria Berg, Richard W. Childs, MD, Roger Kurlander, MD, Jonathan Powell, MD PhD, Griffin P. Rodgers, MD, John F. Tisdale, MD

Blood (2006) 108 (11): 2994.

https://doi.org/10.1182/blood.V108.11.2994.2994

Published: 2006

NARROW

Akt and mTOR Pathways Differentially Regulate the Development of Natural and Inducible IL-17-Producing CD4+ T Cells

Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting

Post-Transplant Cyclophosphamide and Sirolimus Are Synergistic in Preventing Rejection and Inducing Stable Mixed Chimerism Independently of Regulatory T Cells.

Enhanced Interaction Between Hsp90 and Raptor Regulates mTOR Signaling upon T Cell Activation

TOR Complex 1 and TOR Complex 2 Differentially Regulate Effector and Regulatory T Cell Differentiation

A Novel Allogeneic Transplant Conditioning Regimen Designed for Tolerance Induction in Patients with Severe Sickle Cell Disease.

Email alerts

ASH Publications

American Society of Hematology

Akt and mTOR Pathways Differentially Regulate the Development of Natural and Inducible IL-17-Producing CD4+ T Cells

Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting

Post-Transplant Cyclophosphamide and Sirolimus Are Synergistic in Preventing Rejection and Inducing Stable Mixed Chimerism Independently of Regulatory T Cells.

Enhanced Interaction Between Hsp90 and Raptor Regulates mTOR Signaling upon T Cell Activation

TOR Complex 1 and TOR Complex 2 Differentially Regulate Effector and Regulatory T Cell Differentiation

A Novel Allogeneic Transplant Conditioning Regimen Designed for Tolerance Induction in Patients with Severe Sickle Cell Disease.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only